NasdaqGS:ALNYBiotechs
Did New Vutrisiran Data and FCF Breakeven Just Shift Alnylam Pharmaceuticals' (ALNY) Investment Narrative?
In early April 2026, Alnylam Pharmaceuticals highlighted new clinical data for its ATTR-CM therapy vutrisiran at the American College of Cardiology meeting, while also marking free cash flow breakeven in 2025 and continued recognition for its RNAi-based cardiovascular portfolio.
Investor interest was further underlined as a large-cap growth fund added Alnylam to its portfolio, aligning institutional conviction with improving financial footing and reinforcing attention on the company’s...